Pharmacokinetics of oral spironolactone in infants up to 2 years of age.

Purpose: Spironolactone is a potassium sparing diuretic used for decades. Until now, pharmacokinetic (PK) studies of spironolactone have not been conducted in infants and therefore pediatric dosing is based on expert opinion. We aimed to describe the PK profiles of spironolactone and its main metabo...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Clinical Pharmacology Vol. 80; no. 2; pp. 239 - 249
Autores principales: Lass, Jana, Leroux, Stephanie, Kõrgvee, Lenne-Triin, Varendi, Heili, Kipper, Karin, Takkis, Kalev, Aro, Rudolf, Metsvaht, Tuuli, Oselin, Kersti, Pfister, Marc, Soeorg, Hiie, van den Anker, Johannes, Lutsar, Irja
Formato: research tables/charts Journal Article
Publicado: Springer Nature Feb2024
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=175280741&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 175280741
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00316970
        NP9
      jtl: European Journal of Clinical Pharmacology
      issn: 00316970
      maglogo: N
    pubinfo:
      dt: Feb2024
      vid: 80
      iid: 2
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        175280741
        173919443
        175280741
        175280741
        10.1007/s00228-023-03599-w
        175280741
      ppf: 239
      ppct: 10
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Pharmacokinetics of oral spironolactone in infants up to 2 years of age.
      aug:
        au:
          Lass, Jana
          Leroux, Stephanie
          Kõrgvee, Lenne-Triin
          Varendi, Heili
          Kipper, Karin
          Takkis, Kalev
          Aro, Rudolf
          Metsvaht, Tuuli
          Oselin, Kersti
          Pfister, Marc
          Soeorg, Hiie
          van den Anker, Johannes
          Lutsar, Irja
        affil: https://ror.org/03z77qz90 Institute of Pharmacy, University of Tartu, Tartu, Estonia
      sug:
        subj:
          Spironolactone Pharmacokinetics
          Administration, Oral
          Metabolites
          Steroids Pharmacokinetics
          Human
          Infant, Newborn
          Infant
          Prospective Studies
          Chromatography, High Pressure Liquid
          Mass Spectrometry
          Body Weight
          Pediatric Care
          Heart Failure
          Edema
          Drugs, Prescription
          Descriptive Statistics
          Data Analysis Software
          Funding Source
          Spironolactone Blood
          Steroids Blood
          Ascites
          Infant, Newborn: birth-1 month
          Infant: 1-23 months
      ab: Purpose: Spironolactone is a potassium sparing diuretic used for decades. Until now, pharmacokinetic (PK) studies of spironolactone have not been conducted in infants and therefore pediatric dosing is based on expert opinion. We aimed to describe the PK profiles of spironolactone and its main metabolites (7alpha-thiomethylspironolactone (TMS) and canrenone (CAN)) in infants up to two years of age. Methods: The PK of spironolactone and its main metabolites were evaluated following an oral administration of spironolactone (1 mg/kg/dose) to pediatric patients with chronic heart failure, ascites, and/or oedema. The plasma concentration of spironolactone and metabolites (TMS and CAN) was determined using an ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS). Based on rich sampling PK data, the estimation of population PK parameters was performed using nonlinear mixed‐effects modelling software Monolix 2018R2. Results: A total of 150 spironolactone, 158 TMS, and 158 CAN concentrations from 23 patients (ages: 3 days–21 months; median weight 4.3 kg (2.2–12.6)) were available for PK analysis. A one-compartment model for spironolactone, TMS, and CAN best fitted the data. The median (range) of individual estimated apparent clearance values were 47.7 (11.9–138.1) L/h for spironolactone, 9.7 (1.5–66.9) L/h for TMS, and 1.0 (0.2–5.9) L/h for CAN. The disposition of spironolactone and metabolites was mainly affected by size of the patient: body weight explained 22% of inter-individual variability of spironolactone clearance. None of the undesirable effects of spironolactone was documented during the study period. Conclusion: The pharmacokinetics of spironolactone and its metabolites was highly variable between patients below 2 years of age. Body weight explained a significant part of this variability; this highlights the need to take it into account for dosing prescription in this population. (Clinical trial Registration Number 2013–001189-40).
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N